All Stories

  1. The role of phosphate in kidney disease

    Article • Nature Reviews Nephrology, November 2016, Nature

    prof Marc Vervloet

  2. Novel Faces of Fibroblast Growth Factor 23 (FGF23): Iron Deficiency, Inflammation, Insulin Resistance, Left Ventricular Hypertrophy, Proteinuria and Acute Kidney Injury

    Article • Calcified Tissue International, November 2016, Springer Science + Business Media

    prof Marc Vervloet

  3. Response of fibroblast growth factor 23 to volume interventions in arterial hypertension and diabetic nephropathy

    Article • Medicine, November 2016, Wolters Kluwer Health

    prof Marc Vervloet

  4. Phosphate Binding Therapy to Lower Serum Fibroblast-Growth-Factor-23 Concentrations in Chronic Kidney Disease: Rationale and Study Design of the Sevelamer on FGF23 Trial (SoFT)

    Article • July 2016, Karger Publishers

    prof Marc Vervloet

  5. Serum sclerostin: relation with mortality and impact of hemodiafiltration

    Article • Nephrology Dialysis Transplantation, June 2016, Oxford University Press (OUP)

    prof Marc Vervloet

  6. Fibroblast growth factor 23 modifies the pharmacological effects of angiotensin receptor blockade in experimental renal fibrosis

    Article • Nephrology Dialysis Transplantation, May 2016, Oxford University Press (OUP)

    prof Marc Vervloet

  7. Abdominal aortic calcification in patients with CKD

    Article • Journal of Nephrology, March 2016, Springer Science + Business Media

    prof Marc Vervloet

  8. Lack of evidence does not justify neglect: how can we address unmet medical needs in calciphylaxis?

    Article • Nephrology Dialysis Transplantation, March 2016, Oxford University Press (OUP)

    prof Marc Vervloet, Sandro Mazzaferro

  9. The dipeptide alanyl-glutamine ameliorates peritoneal fibrosis and attenuates IL-17 dependent pathways during peritoneal dialysis

    Article • Kidney International, March 2016, Elsevier

    prof Marc Vervloet

  10. Clinical imaging of vascular disease in chronic kidney disease

    Article • International Urology and Nephrology, February 2016, Springer Science + Business Media

    prof Marc Vervloet

  11. Reduction of Oxidative Stress in Chronic Kidney Disease Does Not Increase Circulating α-Klotho Concentrations

    Article • PLoS ONE, January 2016, PLOS

    prof Marc Vervloet

  12. Vitamin D in Chronic Kidney Disease

    Article • January 2016, Springer Science + Business Media

    prof Marc Vervloet

  13. Vitamin D and Anemia in Chronic Kidney Disease

    Article • January 2016, Springer Science + Business Media

    prof Marc Vervloet

  14. Dietary phosphorus restriction in predialysis chronic kidney disease: time for a cease-fire?

    Article • Kidney International, January 2016, Elsevier

    prof Marc Vervloet

  15. α-Klotho is unstable in human urine

    Article • Kidney International, December 2015, Elsevier

    prof Marc Vervloet

  16. Fibroblast growth factor 23 correlates with volume status in haemodialysis patients and is not reduced by haemodialysis

    Article • Nephrology Dialysis Transplantation, November 2015, Oxford University Press (OUP)

    prof Marc Vervloet, MDPhD Casper FM Franssen

  17. Serum Magnesium and Sudden Death in European Hemodialysis Patients

    Article • PLoS ONE, November 2015, PLOS

    prof Marc Vervloet

  18. Effects of Convective Dialysis Techniques on Electrolytes and Mineral Metabolism

    Article • November 2015, Springer Science + Business Media

    prof Marc Vervloet

  19. Soluble klotho and mortality: The Ludwigshafen Risk and Cardiovascular Health Study

    Article • Atherosclerosis, October 2015, Elsevier

    prof Marc Vervloet

  20. Shedding of klotho by ADAMs in the kidney

    Article • AJP Renal Physiology, July 2015, American Physiological Society

    prof Marc Vervloet

  21. Membrane-bound Klotho is not expressed endogenously in healthy or uraemic human vascular tissue

    Article • Cardiovascular Research, June 2015, European Society of Cardiology

    Dr Jan-Luuk Hillebrands, prof Marc Vervloet

  22. Relation between Red Cell Distribution Width and Fibroblast Growth Factor 23 Cleaving in Patients with Chronic Kidney Disease and Heart Failure

    Article • PLoS ONE, June 2015, PLOS

    prof Marc Vervloet

  23. Vitamin D receptor activator and dietary sodium restriction to reduce residual urinary albumin excretion in chronic kidney disease (ViRTUE study): rationale and study protocol

    Article • Nephrology Dialysis Transplantation, March 2015, Oxford University Press (OUP)

    prof Marc Vervloet

  24. Impact of fractional phosphate excretion on the relation of FGF23 with outcome in CKD patients

    Article • Journal of Nephrology, February 2015, Springer Science + Business Media

    prof Marc Vervloet

  25. Fibroblast Growth Factor 23 and the Antiproteinuric Response to Dietary Sodium Restriction During Renin-Angiotensin-Aldosterone System Blockade

    Article • American Journal of Kidney Diseases, February 2015, Elsevier

    prof Marc Vervloet

  26. Protective Effects of Paricalcitol on Peritoneal Remodeling during Peritoneal Dialysis

    Article • BioMed Research International, January 2015, Hindawi Publishing Corporation

    prof Marc Vervloet

  27. A Novel Rat Model of Vitamin D Deficiency: Safe and Rapid Induction of Vitamin D and Calcitriol Deficiency without Hyperparathyroidism

    Article • BioMed Research International, January 2015, Hindawi Publishing Corporation

    prof Marc Vervloet

  28. The Role of Klotho on Vascular Calcification and Endothelial Function in Chronic Kidney Disease

    Article • Seminars in Nephrology, November 2014, Elsevier

    prof Marc Vervloet

  29. New Insights Into the FGF23-Klotho Axis

    Article • Seminars in Nephrology, November 2014, Elsevier

    prof Marc Vervloet

  30. Calcium-Sensing Receptor Activation in Chronic Kidney Disease: Effects Beyond Parathyroid Hormone Control

    Article • Seminars in Nephrology, November 2014, Elsevier

    prof Marc Vervloet

  31. Fibroblast growth factor 23 (FGF23) and mortality: The Ludwigshafen Risk and Cardiovascular Health Study

    Article • Atherosclerosis, November 2014, Elsevier

    prof Marc Vervloet

  32. Reversing Arterial Stiffening and Calcification: A Pipe Dream?

    Article • September 2014, Springer Science + Business Media

    prof Marc Vervloet

  33. Acute Kidney Injury in Intensive Care

    Article • August 2014, World Scientific Pub Co Pte Lt

    prof Marc Vervloet

  34. Citrate anticoagulation versus systemic heparinisation in continuous venovenous hemofiltration in critically ill patients with acute kidney injury: a multi-center randomized clinical trial

    Article • Critical Care, August 2014, Springer Science + Business Media

    prof Marc Vervloet

  35. Bone: a new endocrine organ at the heart of chronic kidney disease and mineral and bone disorders

    Article • The Lancet Diabetes & Endocrinology, May 2014, Elsevier

    prof Marc Vervloet, Sandro Mazzaferro

  36. Dietary and Pharmacological Modification of Fibroblast Growth Factor-23 in Chronic Kidney Disease

    Article • Journal of Renal Nutrition, May 2014, Elsevier

    prof Marc Vervloet

  37. Clinical Uses of 1-alpha-hydroxycholecalciferol

    Article • Current Vascular Pharmacology, April 2014, Bentham Science Publishers

    prof Marc Vervloet

  38. Noncardiovascular mortality in CKD: an epidemiological perspective

    Article • Nature Reviews Nephrology, February 2014, Nature

    prof Marc Vervloet

  39. Fibroblast Growth Factor 23 and Cardiovascular Mortality after Kidney Transplantation

    Article • Clinical Journal of the American Society of Nephrology, August 2013, American Society of Nephrology

    prof Marc Vervloet, Dr. Martin H. De Borst

  40. Continuous venovenous haemofiltration with citrate-buffered replacement solution is safe and efficacious in patients with a bleeding tendency: a prospective observational study

    Article • BMC Nephrology, April 2013, Springer Science + Business Media

    prof Marc Vervloet

  41. Circulating alpha-klotho levels are not disturbed in patients with type 2 diabetes with and without macrovascular disease in the absence of nephropathy

    Article • Cardiovascular Diabetology, January 2013, Springer Science + Business Media

    prof Marc Vervloet

  42. Influence of Four Different PTH Methods on the Classification of Chronic Kidney Disease PatientS According to the New KDIGO Guideline

    Article • Clinical Laboratory, January 2013, Clinical Laboratory Publications

    prof Marc Vervloet

  43. Correction: Circulating alpha-klotho levels are not disturbed in patients with type 2 diabetes with and without macrovascular disease in the absence of nephropathy

    Article • Cardiovascular Diabetology, January 2013, Springer Science + Business Media

    prof Marc Vervloet

  44. The role of vitamin D in cardiovascular disease: From present evidence to future perspectives

    Article • Atherosclerosis, December 2012, Elsevier

    prof Marc Vervloet

  45. Fibroblast growth factor 23 is associated with proteinuria and smoking in chronic kidney disease: An analysis of the MASTERPLAN cohort

    Article • BMC Nephrology, April 2012, Springer Science + Business Media

    prof Marc Vervloet

  46. A multidisciplinary review of the science of vitamin D receptor activation

    Article • Kidney International Supplements, September 2011, Elsevier

    prof Marc Vervloet

  47. Fibroblast growth factor-23 and Klotho in chronic kidney disease

    Article • Kidney International Supplements, September 2011, Elsevier

    prof Marc Vervloet

  48. Erratum to “Delivered dose of continuous venovenous hemofiltration predicts outcome in septic patients with acute kidney injury: A retrospective study”

    Article • Journal of Critical Care, August 2011, Elsevier

    prof Marc Vervloet

  49. Underdosing continuous venovenous hemofiltration predicts outcome in septic patients with acute kidney injury

    Article • Journal of Critical Care, April 2011, Elsevier

    prof Marc Vervloet

  50. Delivered dose of continuous venovenous hemofiltration predicts outcome in septic patients with acute kidney injury: A retrospective study

    Article • Journal of Critical Care, April 2011, Elsevier

    prof Marc Vervloet

  51. Predilution versus Postdilution Continuous Venovenous Hemofiltration: No Effect on Filter Life and Azotemic Control in Critically Ill Patients on Heparin

    Article • ASAIO Journal, January 2011, Wolters Kluwer Health

    prof Marc Vervloet

  52. Determinants of Outcome in Non-Septic Critically Ill Patients with Acute Kidney Injury on Continuous Venovenous Hemofiltration

    Article • Nephron Extra, January 2011, Karger Publishers

    prof Marc Vervloet

  53. A dose-finding study of methylene blue to inhibit nitric oxide actions in the hemodynamics of human septic shock

    Article • Nitric Oxide, May 2010, Elsevier

    prof Marc Vervloet

  54. Metabolic effects of citrate- vs bicarbonate-based substitution fluid in continuous venovenous hemofiltration: A prospective sequential cohort study

    Article • Journal of Critical Care, March 2010, Elsevier

    prof Marc Vervloet

  55. Treatment of septic renal injury by alkaline phosphatase: An emperor with new clothes*

    Article • Critical Care Medicine, February 2009, Wolters Kluwer Health

    prof Marc Vervloet

  56. Continuous Venovenous Hemofiltration with or without Predilution Regional Citrate Anticoagulation: A Prospective Study

    Article • Blood Purification, August 2007, Karger Publishers

    prof Marc Vervloet

  57. Mycophenolate Mofetil in Idiopathic Membranous Nephropathy: A Clinical Trial With Comparison to a Historic Control Group Treated With Cyclophosphamide

    Article • American Journal of Kidney Diseases, August 2007, Elsevier

    prof Marc Vervloet

  58. Lipopolysaccharide Concentrations During Superflux Dialysis Using Unfiltered Bicarbonate Dialysate

    Article • ASAIO Journal, July 2002, Wolters Kluwer Health

    prof Marc Vervloet

  59. Gastric tonometry in the fed or fasting state?

    Article • Critical Care Medicine, December 1998, Wolters Kluwer Health

    prof Marc Vervloet

  60. Derangements of Coagulation and Fibrinolysis in Critically III Patients with Sepsis and Septic Shock

    Article • Seminars in Thrombosis and Hemostasis, February 1998, Thieme Publishing Group

    prof Marc Vervloet

  61. The Kidney in Sepsis

    Article • Springer Science + Business Media

    prof Marc Vervloet

  62. Hormonal changes induced by changing amounts of protein and phosphorus in the diet of healthy volunteers

    Article • Springer Science + Business Media

    prof Marc Vervloet